Our collective understanding of the immune system is constantly expanding as more and more high-quality studies are published each day. At ImmPort, we are proud to provide a platform that preserves this data for re-use by the greater scientific community. Recently, 9 new studies were added to ImmPort and 5 existing studies were updated, bringing ImmPort’s total study count to 422. ImmPort now contains high quality immunological-related data for over 58,000 subjects representing over 5 million experimental results.

Read more →

Our hearts and minds are with all impacted by COVID-19, and we’d like to ensure those in the research community are aware of the high quality immunological data available for immediate use in ImmPort. ImmPort is a robust data repository sponsored by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID). Data within ImmPort has been generated largely through clinical trials and research studies funded by the NIH and other public-private partnerships, and all data is freely available for re-use.

Read more →

With 22 new studies and 21 updated studies, the latest release of ImmPort contains a wealth of high quality data, all free for re-use. This major release contains data from over 2,700 subjects and covers a wide range of research areas such as food allergies, organ and islet transplantation, lupus, HIV, chikungunya, and vaccine response for influenza and pertussis. Of the 22 new studies, 6 come from the Consortium for Food Allergy Research (CoFAR) and contain data from 1,587 subjects.

Read more →

ImmPort at BigDat 2020

ImmPort is always thrilled to support bioinformatics and big data researchers around the world. In just such an instance, ImmPort Science Program Lead Sanchita Bhattacharya, @SanchitaB, from the Bakar Institute of Computational Health Sciences, UCSF, will be teaching during the 6th International BigDat 2020 program in Ancona, Italy. BigDat 2020 is a research training event with a focus on updating participants on the latest advances in big data utilization and sub-areas such as infrastructure, management, search and mining, security and privacy, and applications.

Read more →

ImmPort at FORCE2019: Edinbough, Scotland

Findable, Accessible, Interoperable, and Responsible (FAIR) data principals are at the core of ImmPort’s mission. This driving force intersects well with another force, FORCE11 that is, which stands for the Future of Research Communications and e-Scholarship, a group founded in 2011 to “improve research practices by supporting innovations in the ways knowledge is created and shared across research disciplines, communities, sectors and timeframes.” ImmPort’s own Scientific Program Director, Dr. Sanchita Bhattacharya @SanchitaB, was honored to share a poster presentation during FORCE11’s annual conference in Edinbough, Scotland.

Read more →

What if clinicians could understand earlier in pregnancy which mothers are developing preeclampsia, far before any clinical symptoms emerge? A team of researchers discovered that a set of eight cell-specific immune features from a maternal blood sample accurately predicted the onset of preeclampsia well before traditional clinical signs appeared. These results are captured in ImmPort study SDY1528, and are as always, freely available for download and re-use. Preeclampsia is a leading cause of maternal death and preterm birth, however early diagnosis has been challenging.

Read more →

What conditions do living donors experience in the years following solid-organ donation? This is a question immTransplant seeks to understand using data from 27 clinical studies in the ImmPort database. By providing this information in an open access format, researchers can leverage the data to understand which conditions living donors may experience up to 40 years down the road. Additionally, a trajectory network map shows relationships between conditions; for example, how frequently one condition progresses to another.

Read more →

With 9 new studies and 7 updated studies, the latest release of ImmPort contains shared data (ready for free re-use) from thousands of experimental samples. Research focus areas include vaccine response, allergy, asthma, and preterm birth. Assay types including ELISA, ELISPOT, RNA sequencing, flow cytometry, and many more. One new shared study, SDY1086, presented novel insights into how the gut microbiome impacts vaccine response in humans. Per the study summary published in Cell, researchers administered a seasonal influenza vaccine to a group of healthy adults who were given a course of broad-spectrum antibiotics, and also administered the vaccine to a control group of healthy adults not receiving antibiotics.

Read more →

How to Explore ImmPort Data Visually

Bringing data to life through visualization is a powerful tool for discovery, and the ImmPort team is proud to add this capability to the ImmPort user experience. In one quick glance, users can now explore data in bubble chart format by research focus area, and drill down to find datasets by assay type. Additionally, users can visualize other aspects of study data by clicking any numbers with a pie chart icon at the top of the Shared Data homepage.

Read more →

What can the Immune Epitope Database (IEDB) do for your research? With over two million experiments and hundreds of thousands of epitopes stored, the IEDB provides an invaluable free resource to researchers worldwide. Dr. Bjoern Peters, PhD and co-leader of the IEDB and Professor for the La Jolla Institute of Allergy and Immunology, gave an information-packed talk during FOCIS on the wealth of information within the IEDB. The IEDB is one of the world’s largest catalogues of epitopes, which are the specific molecular structures used by the immune system to recognize unwanted visitors such as viruses and bacteria.

Read more →